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Abstract
Rationale—Orexins are neuropeptides released in multiple brain regions from neurons that 
originate within the lateral hypothalamus and contiguous perfornical area. The basal forebrain, a 
structure implicated in attentional processing, receives orexinergic inputs. Our previous work 
demonstrated that administration of an orexin-1 receptor antagonist, SB-334867, systemically or 
via infusion directly into the basal forebrain, can disrupt performance in a task that places explicit 
demands on attentional processing.
Objectives—Given that the orexin-1 receptor binds orexin A with high affinity, we tested 
whether orexin A could enhance attention in rats.
Methods—Attentional performance was assessed using a task that required discrimination of 
variable duration visual signals from trials when no signal was presented. We also tested whether 
infusions of orexin A into the lateral ventricle could attenuate deficits following lesions of medial 
prefrontal cortical cholinergic projections that arise from the basal forebrain.
Results—Infusions of orexin A into the basal forebrain attenuated distracter-induced decreases 
in attentional performance. Orexin A attenuated deficits in lesioned animals when a visual 
distracter was presented.
Conclusion—The present results support the view that orexin A can enhance attentional 
performance via actions in the basal forebrain and may be beneficial for some conditions 
characterized by attentional dysfunction due to disruption of cortical cholinergic inputs.
Keywords
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Introduction
Since the initial reports of the discovery of orexins (de Lecea et al. 1998; Sakurai et al. 
1998), these neuropeptides have been associated with numerous processes, including sleep, 
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hunger and drug abuse (Mahler et al. 2012; Ritchie et al. 2010; Sakurai et al., 1998; 
Thannickal et al. 2000). The role of orexins in attentional processing has also been 
investigated, with emphasis on the projections to the basal forebrain (Arrigoni et al. 2010; 
Fadel & Burk 2010). Loss of orexin neurons disrupts acquisition of conditioned orienting 
responses (Wheeler et al. 2014). Administration of an orexin-1 receptor antagonist, 
SB-334867, systemically or directly into the basal forebrain disrupts attentional performance 
(Boschen et al. 2009). These findings have supported the idea that orexins may be useful for 
treating cognitive deficits associated with disruption of cortical cholinergic projections, such 
as in Alzheimer's Disease (Fadel et al. 2013; Fronczek et al. 2012; Slats et al. 2012; 
Wennstrom et al. 2012).
The orexin-1 receptor has a much higher affinity for binding orexin A compared with orexin 
B (Sakurai et al. 1998). Intranasal or intravenous administration of orexin A can attenuate 
cognitive deficits following sleep deprivation in nonhuman primates (Deadwyler et al. 
2007). Additionally, orexin A is thought to play an important role in different forms of 
learning and memory (Akbari et al. 2006, 2007; Aou et al. 2003; Jaeger et al. 2002; 
Piantadosi et al. 2015; Yang et al. 2013; but see also Dietrich & Jenck 2010). Although the 
evidence is somewhat mixed, overall, it appears that orexin A can reverse cognitive deficits 
under some conditions. However, the neural mechanisms for these effects of orexin A 
remain unclear. Basal forebrain corticopetal cholinergic neurons are known to be necessary 
for attentional performance. For example, immunotoxic lesions of these neurons disrupt 
signal detection in several attention-demanding tasks (McGaughy et al. 1996, 2002). 
Moreover, cortical acetylcholine release is increased during attention-demanding tasks 
(Arnold et al. 2002; Passetti et al. 2000). Using choline-sensitive biosensors, prefrontal 
cortical cholinergic transients are larger on trials with accurate signal detection following a 
previous trial when a response associated with a nonsignal was made (Howe et al. 2013). 
However, it is unknown whether the basal forebrain is part of the neural circuitry that 
mediates any attention-enhancing effects of orexin A. Moreover, the ability of orexin A to 
attenuate attentional deficits associated with damage to corticopetal cholinergic neurons is 
not well-studied.
In the present experiments, rats were trained in a two-lever task that required discrimination 
of brief, variable visual signals from trials when no signal was presented (Bushnell et al. 
1994; McGaughy & Sarter 1995). This task was selected because of the sensitivity of the 
task to manipulations of basal forebrain corticopetal cholinergic neurons (e.g., McGaughy et 
al. 1996, 1998) and because of recent reports that demonstrated the translational potential 
and use of this task in multiple species, including mice (St. Peters et al. 2011) and humans 
(Bushnell et al. 2003; Demeter et al. 2008; Howe et al. 2013). The effects of infusions of 
orexin A directly into the basal forebrain were examined in a well-trained version of the task 
and with attentional demands increased by presenting a visual distracter. Given that orexins 
innervate multiple regions and the clinical interest associated with these neuropeptides, in a 
subsequent experiment, orexin A was infused into the lateral ventricle prior to attention task 
performance following loss of medial prefrontal cortical cholinergic inputs.
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Materials and Methods
Subjects
Male FBNF1 hybrid rats, 151-175 g at the beginning of the experiment were used (National 
Institute of Aging Colony). The rats were individually housed in a vivarium which was 
temperature and humidity controlled and operated on a 14:10 hour light/dark cycle (lights on 
0600). All rats were water restricted throughout the experiment, receiving water during 
behavioral testing and for 30 minutes after each testing session. Rats were trained five to 
seven days a week, and received at least one hour of water access on days when no 
behavioral testing occurred. Food was provided ad libitum throughout the experiment. 
Animals were treated in accordance with the guidelines of the Animal Care and Use 
Committee at the College of William and Mary.
Apparatus
Rats were trained in one of 12 chambers, each located within a sound attenuating box (Med 
Associates, Inc.). Each chamber contained a water port positioned with a dipper that could 
be raised to provide water access (0.01 ml tap water). Two retractable levers were located on 
either side of the water port. A panel light was located above each lever and above the water 
port. A house light was positioned on the opposite side of each chamber. Illumination levels 
of these chambers have been described (Burk 2004). Behavioral testing programs and data 
collection was controlled by a personal computer using the Med-PC version IV software.
Presurgical attention task training
Training occurred between 9:00 a.m. and 12:00 p.m. daily. In the initial shaping procedure, 
rats were trained to press an extended lever using an FR-1 schedule of reinforcement, with 
the rule, to prevent a side bias, that if one lever was pressed five consecutive times, the other 
lever had to be pressed to receive water access. Once animals received 120 rewards in a 
session for three sessions, they were moved to the next training stage, where there were two 
trial types, signal (1-s illumination of the central panel light) and nonsignal (no illumination 
of the central panel light) trials. One second following a signal or no signal, the rats were 
cued to respond by extension of the levers into the chamber. Rules for training were 
counterbalanced, such that half of the rats were reinforced (3-s access to 0.01ml tap water) 
for pressing the left lever following a signal, which was recorded as a hit. A miss was 
recorded for right lever presses after a signal. For nonsignal trials, a press of the right lever 
was considered a correct rejection and water access was provided, while a press of the left 
lever on these trials was recorded as a false alarm. The rules of the task were reversed for the 
other half of the rats such that a right lever press was considered a hit following a signal 
presentation whereas the left lever was considered a correct response on a nonsignal trial. 
The inter-trial interval (ITI) was 12-s and the houselight was illuminated throughout the 
session during this stage of training. An incorrect response during this training phase would 
be followed by a correction trial which was the same trial type as that in which the error 
occurred. If the rat responded incorrectly for three consecutive trials, a forced trial occurred 
in which only the correct lever was extended into the chamber for 90-s or until the rat 
responded. If the errors occurred on signal trials, the central panel light was illuminated 
while the lever was extended. Each session lasted for 45 min and rats were trained with this 
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task until reaching a criterion of >70% accuracy on signal and nonsignal trials for three 
consecutive sessions.
After reaching criterion, rats were moved to the final stage of training prior to surgery. In the 
final task, the signal durations (500, 100, 25 ms) and ITI (9 ± 3 s) were shorter and varied in 
order to increase explicit attentional demands (Parasuraman et al., 1987; Koelega et al. 
1990). Each training session was comprised of 162 total trials (81 signal, 81 non-signal). For 
the signal trials, each of the three signal durations was presented for 27 trials within a 
session. Trials were presented in blocks of 18 (9 non-signal, 9 signal, with 3 of each signal 
duration) and trial types were selected randomly without replacement. Rats were considered 
trained for surgery when a criterion of >70% accuracy on trials when the 500-ms signal was 
presented and on nonsignal trials for three consecutive sessions.
Surgical procedures
On the night prior to surgery, rats were provided with 2.7 mg/ml acetaminophen in their 
drinking water. Rats were anesthetized via ip injections of 90.0 mg/kg ketamine combined 
with 9.0 mg/kg xylazine. Once the rats were sufficiently anesthetized, the surgical area was 
shaved and rats were positioned in a stereotaxic device with the incisor bar set at 3.3 mm 
below the interaural line. All surgical procedures were conducted under aseptic conditions. 
In one experiment, rats received bilateral implantation of guide cannulae into the basal 
forebrain. For these rats, 8-mm guide cannulae (22 gauge) were implanted at −1.3mm 
anterior-posterior (AP) and ± 2.7mm medial-lateral (ML) from bregma and −4.2mm from 
dura. In a second experiment, rats received infusions of 192IgG-saporin (0.2 μg/μl; 0.5μl per 
site) or saline into the medial prefrontal cortex (3.7mm and 2.6mm AP, ±0.7mm ML; −3.5 
mm DV; AP and ML from bregma, DV from dura) and a single guide cannula (hemisphere 
was randomized across rats) to allow infusions into the lateral ventricle (−0.8mm AP, + or 
−1.6mm ML from bregma; −2.5mm DV from dura). Three stainless steel screws and dental 
cement were also used to secure the cannulae. For rats that received infusions into the 
medial prefrontal cortex, bone wax was applied above the skull holes to prevent the dental 
cement from entering these holes. Dummy cannulae were inserted to prevent blockage 
within the guide cannulae. Following surgery, animals were given a one week recovery 
period in which food and water were available ad libitum. Rats were then returned to water 
restriction and began to retrain on the attention task.
Postsurgical behavioral testing procedures prior to orexin A administration
Rats that received bilateral basal forebrain cannulation were retrained in the same attention 
task as before surgery. After re-establishing criterion performance, rats were exposed to two 
sham infusion sessions, in which a short (5-mm) internal cannula, attached to tubing, was 
inserted. The rats were then exposed to a form of the attention task where the houselight was 
flashed (1-s on/1-s off) during the middle block of trials within a testing session (trials 
55-108).
Rats that received lateral guide cannula implantation and infusions of 192IgG-saporin or 
saline into the medial prefrontal cortex were trained in the same attention task as before 
surgery for 15 sessions to establish any baseline effects of the lesion. Based upon previous 
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findings, no effects of the lesion were expected on baseline task performance (Newman & 
McGaughy 2008). Rats were then exposed to two sham infusion sessions with the flashing 
houselight distracter during the middle block of trials, similar to rats with bilateral basal 
forebrain cannulae implantation. After these sham infusion sessions, all rats were considered 
ready for orexin A infusions.
Drug Administration Procedures
Infusions were made through the insertion of an internal cannula attached to a Hamilton 
syringe by polyethylene tubing. A total volume of 0.5 μl solution was infused into each 
cannula at a rate of 1.0 μl/min. The internal cannula was left in place for one minute 
following the completion of each infusion to allow for drug diffusion. Animals were then 
immediately loaded into the chambers to begin behavioral testing. At least one day of 
training was allowed between each testing session to re-establish baseline performance. 
Orexin A (Tocris, Inc.) was dissolved in saline and alliquotted into small vials that were 
stored at −20° until being used for an infusion. Each vial was used only once on an infusion 
day and thus, orexin A was not repeatedly thawed and frozen. Rats with bilateral basal 
forebrain implantation received 0.0 (saline), 0.1pM, 1.0pM, 10pM orexin A (Fadel et al. 
2005) via internal cannulae (28 gauge) that extended 3.0 mm beyond the guide cannulae, 
with each dose being administered one time prior to task performance in an order that was 
randomized for each rat. The infusion procedures for rats receiving intracerebroventricular 
infusions were similar, except that the orexin A doses were increased (0, 10pM, 100pM, 
1000pM) via an internal cannula that extended 1.0 mm beyond the guide cannula. On drug 
infusion sessions, rats were tested in a version of the attention task with the flashing 
houselight distracter presented during the second block of trials (trials 55-108) within the 
session.
Histological procedures and analysis
After being deeply anesthetized via an ip injection of 100.0 mg/kg ketamine and 10.0 mg/kg 
xylazine, rats were transcardially perfused with 10% sucrose followed by 10% formalin (for 
rats with bilateral basal forebrain guide cannulae implanted) or 4% paraformaldehyde (for 
sham- or 192IgG-induced lesions and lateral ventricle guide cannula implanted) at a 
pressure of 300mmHg using a Perfusion One apparatus. The brains were then removed and 
placed in the same fixative for 48 hours before being put into a 30% sucrose solution in 
phosphate buffered saline for at least three days. The tissue was then sectioned in 50 μM 
slices using a freezing microtome. For rats with bilateral guide cannulae in the basal 
forebrain, sections nearest the cannula sites were stained using cresyl violet and viewed 
under a microscope to assess cannula placement. For rats with cholinergic lesions or sham-
lesions, sections near the medial prefrontal cortex were stained for acetylcholinesterase 
(AChE) positive fibers and cannula location was also confirmed. AChE histochemistry was 
performed using a modification of previous procedures (Tago et al. 1986) and similarly to 
previous work in our laboratory (Burk et al. 2008). Sections were first rinsed in a 0.1 M 
phosphate buffer solution and then incubated in hydrogen peroxide for 20 minutes. After a 
rinse in maleate buffer, sections were immersed in a solution composed of 0.5 ml of 0.1 M 
sodium citrate, 1.0 ml of 5 mM potassium ferricyanide, 1.0 ml of 30 mM cupric sulfate, 10.0 
mg of acetylthiocholine and 197.5 ml of 0.1 M maleate buffer for 45 minutes. After rinsing 
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in 50.0 mM Tris buffer (pH 7.6), sections were incubated for 10 min in the solution prepared 
using the provided instructions in a diaminobenzidine (DAB) kit with nickel ammonium 
sulfate added. At the end of the incubation period, drops of 0.1% hydrogen peroxide were 
added to the sections until tissue staining was complete. These sections were mounted on 
gelatin coated slides, dehydrated and then coverslipped.
AChE-positive fibers were quantified in the prelimbic region of the medial prefrontal cortex 
as well as the primary motor (M1) regions in sections from both lesioned and sham lesioned 
animals. AChE-positive fiber density was quantified using a modified counting grid method 
(Stichel & Singer 1987), similar to previous experiments in our laboratory and others (e.g., 
Burk et al. 2008; McGaughy et al. 1996; McGaughy & Newman 2008). Using an Olympus 
BX-51 light microscope with an objective lens magnification of 40X, three lines that 
bisected each other at the midpoint were placed over the image using the Grid Mask 
function in ImagePro Discovery. Grid parameters were set to a radius of 400 with segments 
of 10. Image size was set to 50%. Each time a fiber crossed the lines was counted in at least 
two sections in each hemisphere for all animals. The raw values were averaged together and 
used to estimate lesion extent.
Behavioral Measures and Statistical Analyses
The number of hits (H), misses (M), correct rejections (CR), false alarms (FA) and 
omissions were recorded for each animal during each testing session. The relative number of 
hits [H/(H+M)] and false alarms [FA/(FA+CR)] were calculated. A sustained attention score 
(SAT) was then calculated to take into account accuracy on signal and nonsignal trials in 
which a lever press occurred. SAT was calculated using the following formula: SAT=((H-
FA)/(2x(H+FA)-(H+FA)2) (Boschen et al. 2009; McGaughy et al. 1996). The range of 
scores for the SAT measure is from −1 to 1, where a score of 1 indicates 100% correct 
responses on signal and non-signal trials and a value of 0 indicates an inability to 
discriminate between signal and non-signal trials. To assess accuracy separately on signal 
and nonsignal trials, the percentage of hits and correct rejections were calculated. During 
orexin A infusion sessions, the baseline version of the task, with the houselight consistently 
illuminated, occurred for the first 54 trials and then, for the next 54 trials, the houselight was 
flashed as a distracter. To determine the effect of the distracter for each rat, for each measure 
the difference between block 1 (standard task with no distracter) and block 2 (distracter 
presentation) was calculated as a distracter score. Positive values indicate greater accuracy 
during block 1 and that the distracter decreased performance. Omissions were analyzed 
separately from measures of accuracy.
Data were analyzed with mixed factor ANOVAs, that included factors dose, lesion and 
signal duration (where appropriate). Significant interactions were followed up by 1- or 2-
way ANOVAs followed by t-tests. Data were analyzed with SPSS 19.0 for Windows (SPSS, 
Chicago, IL, USA). A level of α=0.05 was used as the criterion for statistical significance 
and was adjusted using a modified Bonferroni procedure when multiple t-tests were 
conducted (Keppel 1991).
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Results
Effects of orexin A infused bilaterally into the basal forebrain
A total of 10 rats were included in this experiment. Only rats with appropriate cannulae 
placements (Figure 1) and that maintained criterion task performance between infusion 
sessions (n=6) were included in these analyses. Intrabasalis orexin A did not affect 
performance on the standard task without the distracter (block 1). A dose (0, 0.1, 1.0, and 
10pM orexin A) × signal duration (500, 100, 25ms) ANOVA for the SAT measure yielded 
no significant effects of orexin A during block 1. Similar analyses were conducted for the 
relative hits, as well as for nonsignal trials and omission rates. These analyses also yielded 
no significant effect of drug dose on any of these measures during the first block of trials.
Distracter scores were calculated for each rat for each behavioral measure to assess the 
effects of the distracter. This measure indicated the impairment in performance in response 
to the visual distracter presented during block 2, with positive scores representing a more 
substantial decrease in attentional performance when the distracter was presented. A dose × 
signal duration ANOVA did not yield main effects of either factor, but there was a 
significant dose × signal duration interaction (F(6,30) = 2.866, p < .05, η2 = .16) for the 
difference score SAT measure. Follow up analyses revealed a significant main effect of dose 
on trials when the 500ms signal was presented (F(3,15)= 6.668, p < .05, η2 = .57), but not at 
the 100ms or 25ms signal durations (Figure 2). This effect was mirrored by a dose × signal 
duration ANOVA for accuracy on signal trials. For hits, there was not a significant main 
effect of either factor, but the analysis did yield a significant dose × signal duration 
interaction for the distracter score (F(6,30) = 2.849, p<.05, η2 = .). Separate one-way 
ANOVAs including dose as a factor were conducted for each signal duration. These 
analyses yielded a main effect of dose at the 500ms signal duration (F(3,15) = 6.697, p < .
05, η2 = .), but not on 100ms or 25ms signal trials. Further analyses via paired sample t-tests 
compared each orexin A dose with vehicle administration. Performance following 10 pM 
orexin A was significantly different compared to vehicle at the longest (500 ms) signal 
duration (t(5)=2.711, p < .05, d = 1.11). Thus, at the longest (500 ms) signal duration, the 
10pM orexin A dose decreased the distracter score for relative hits compared with vehicle 
administration. There were no significant effects of orexin A dose on correct rejections or 
omissions for the distracter score. Finally, dose × signal duration ANOVAs for the SAT 
measure, relative hits, correct rejections, and omissions on the standard task following the 
distracter (block 3) did not yield any significant results.
Histological analyses of rats with medial prefrontal cortical infusions of 192IgG-saporin or 
saline
A total of 19 rats maintained stable performance throughout drug administration (n=9 sham-
lesioned rats and n=10 lesioned rats). On average, lesioned animals showed a 60.8% loss of 
AChE-positive fibers in the medial prefrontal cortex compared to sham lesioned animals 
(Figure 3). To assess whether the lesions produced a significant decrease in AChE fiber 
staining, t-tests comparing the mean AChE fiber counts from the medial PFC and M1 
regions were conducted. This analysis confirmed that lesioned animals showed significantly 
fewer AChE fibers in the prelimbic region of the medial prefrontal cortex compared with 
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sham-lesioned animals (t(17)=10.769, p < .001, d = 10.8; mean ± SEMs for AChE-positive 
fiber counts: sham-lesioned animals, 61.18 ±3.61; lesioned animals, 23.98 ±1.62) but not in 
the primary motor cortex (p > .79; mean ± SEMs for AChE-positive fiber counts: sham-
lesioned animals, 61.59 ± 2.79; lesioned animals, 60.68 ± 2.07).
Performance of lesioned or sham-lesioned rats prior to orexin A infusions
No significant differences in measures of task performance were observed between lesion 
and sham-lesion groups on the three days prior to surgery. For the 15 sessions immediately 
after surgical recovery, performance was examined averaging measures from three 
consecutive sessions (e.g., average of sessions 1-3, average of sessions 4-6, etc.). For 
relative hits, a repeated-measures session (5 levels) × signal duration (3 levels) × lesion (2 
conditions) ANOVA did not yield any effects involving lesion. The lesioned animals did 
demonstrate a significant decrease in correct rejections compared to the sham-lesioned 
animals (F(1,17) = 5.962, p < .05, η2 = .26), an effect that was significant during sessions 
1-3 (t(17) = 2.452, p < .05, d =1.0) and sessions 4-6 (t(17) = 2.223, p < .05, d = .93), but not 
during subsequent testing sessions (all p > .15; Figure 4). There were no effects involving 
lesion on omissions. Thus, immediately after surgery, lesioned rats demonstrated a transient 
decrease in correct rejections but the performance of this group was not significantly 
different from sham-lesioned animals after 15 postsurgical testing sessions.
Effects of orexin A infusions on attention task performance of lesioned and sham-lesioned 
rats
Following drug infusion, animals omitted nearly all trials following the highest orexin dose 
(1000 pM), rendering the measures of accuracy difficult to interpret for this dose. Therefore, 
measures of accuracy were analyzed only for sessions when 0 (vehicle), 10pM or 100pM 
orexin A was administered. For the SAT measure, a lesion × dose (0, 10, 100pM orexin A) 
× signal duration ANOVA for the first block of trials yielded a significant lesion × dose × 
block interaction (F(4,64) = 2.983, p < .05, η2 = .17). No other main effects or interactions 
involving lesion or dose were significant. The basis for this interaction appeared to be 
differences at the 25ms signal duration, however follow up analyses did not reveal any 
statistically significant differences between lesioned and sham-lesioned animals. A similar 
analysis was conducted for relative hits, correct rejections, and omissions during block 1 of 
trials and yielded no significant effects involving lesion or dose. The distracter score was 
calculated for each behavioral measure similarly to those rats that received bilateral 
infusions of orexin A into the basal forebrain. For SAT, a lesion × dose (0, 10, 100pM 
orexin A) × signal duration ANOVA yielded a lesion × dose × signal duration interaction 
which was approaching significance (F(4,64) = 2.313, p = 0.067). There were no significant 
main effects or other interactions including lesion or dose. For relative hits, a lesion × dose × 
signal duration, revealed a significant lesion × dose × signal duration interaction (F(4,68) = 
2.656, p < .05, η2 = .14) for the distracter score, but no main effects or other interactions 
involving lesion or dose. This interaction was further assessed by conducting separate dose 
× lesion ANOVAs at each signal duration. For relative hits, there was a significant dose × 
lesion interaction (F(2,34) = 4.965, p < .05, η2 = .21), but no significant main effects, at the 
25-ms signal duration, but not on 500-ms or 100-ms signal trials. This dose × lesion 
interaction was further assessed with separate one-way ANOVAs for dose for sham-lesioned 
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and lesioned animals on 25-ms signal trials. No significant effects of dose were observed for 
the sham-lesioned animals (p > .50). There was, however, a significant main effect of dose 
on accuracy at the 25-ms signal duration for the lesioned group (F(2,18) = 6.922, p < .05, η2 
= .43). To clarify the nature of this effect, paired sample t-tests comparing each orexin A 
dose with vehicle administration were conducted for the lesioned animals. These analyses 
yielded a significant difference in the distracter scores when vehicle administration was 
compared with 100 pM orexin A (t(9) = 2.973, p < .05, d = .94). Thus, at the 25 ms signal 
duration, the 100pM orexin A dose decreased the distracter score for relative hits compared 
with vehicle administration, indicating that the lateral ventricle infusions of 100pM orexin A 
may reduce distractibility at the 25ms level (Figure 5). There were no significant effects of 
orexin A dose on correct rejections or omissions for the distracter score. Finally, lesion × 
dose × signal duration ANOVAs for the SAT measure and relative hits as well as lesion × 
dose ANOVAs for correct rejections and omissions on the standard task following the 
distracter (block 3) did not yield any significant effects involving dose or lesion.
Discussion
The present experiments tested whether orexin A could enhance attentional performance via 
direct infusions into the basal forebrain and, in a separate experiment, via intraventricular 
infusion following sham- or 192IgG-saporin-induced lesions of cholinergic projections to 
the medial prefrontal cortex. The present results extend previous findings by showing that 
attention-demanding aspects of task performance benefit the most from orexin A and by 
demonstrating that changes in attentional performance following loss of medial prefrontal 
cortex cholinergic inputs can be attenuated by orexin A.
In both experiments, beneficial effects of orexin A on attentional performance were 
observed when a visual distracter was presented. Thus, orexin A does not appear to enhance 
performance in a well-trained version of the task, but rather when attentional demands are 
augmented by a visual distracter. Moreover, the benefits of orexin A were not observed 
during the final block of trials, when subjects are recovering from the effects of the 
distracter. The orexin A-induced performance enhancement specifically during the distracter 
condition suggests that the drug effects were not some general increase in arousal that 
improved all aspects of the task or specific facilitation of motivation. This conclusion is 
further supported by a lack of effects of orexin A on omissions.
Selective lesions of basal forebrain corticopetal cholinergic neurons typically decrease 
signal detection in this task (e.g., McGaughy et al. 1996, 1999). In the present study, the 
beneficial effects of orexin A were primarily observed on signal trials. These results 
potentially support the conclusion that the beneficial effects of orexin A are mediated via 
corticopetal cholinergic inputs. However, caution should be taken with this interpretation 
because orexins are also released onto basal forebrain noncholinergic neurons. The role of 
basal forebrain noncholinergic neurons in attention, and their interactions with cholinergic 
neurons, remains poorly understood (Sarter & Bruno 2002). Additionally, the obvious 
possibility exists that icv orexin A administration led to beneficial effects by actions outside 
of basal forebrain corticopetal neurons (Peyron et al. 1998). Lambe et al. (2005), for 
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example, have demonstrated a pro-attentional effect of orexins mediated by orexin-2 
receptors on thalamo-prefrontal projections.
When infused into the basal forebrain, orexin A increased the decline in performance on 
trials when the 500-ms signal was presented. Interestingly, this corresponds well with our 
previous work, showing that orexin-1 receptor blockade decreases accuracy on trials with a 
longer signal duration (Boschen et al. 2009). We previously suggested that this pattern of 
deficits reflected disrupted processing of the task rules for signal trials, rather than signal 
perception. If rule processing is affected, then the change in performance would be predicted 
to occur following the longest signal, because this is the signal that the subject is most likely 
to detect. Collectively, we see that orexin receptor blockade and orexin A administration 
bidirectionally affect accuracy on 500-ms signal trials, although we did not find that orexin 
receptor blockade selectively affected accuracy on trials with a distracter (Boschen et al. 
2009). The receptors responsible for the effects of orexin A require further investigation. 
Orexin A binds to both orexin 1 and orexin 2 receptors (Sakurai et al. 1998) and these 
receptors are expressed at similar levels in the basal forebrain (Marcus et al. 2001). The 
present effects of orexin A could be due to actions at orexin 1 or orexin 2 receptors, or 
activation of both of these receptor subtypes.
Lesions of the cholinergic projections to the medial prefrontal cortex transiently decreased 
correct rejections. It is somewhat surprising that the lesions affected accuracy on nonsignal, 
rather than signal trials, but the difference in performance supports that the lesions were 
effective. The extent of lesions was similar to previous studies in which this immunotoxin 
was infused into the medial prefrontal cortex (Newman & McGaughy 2008). As expected, 
the lesioned and sham lesioned animals’ performance did not differ during the final sessions 
prior to orexin A administration. Lesioned animals demonstrated improvement in detecting 
the 25 ms signal following 100 pM orexin A compared with vehicle administration when the 
distracter was presented. The 25 ms signal may be considered the most challenging to 
detect. Thus, the beneficial effects of orexin A for lesioned animals’ performance are 
prominent during the highest attentional demands, both in terms of increased background 
noise and signal duration. The beneficial effects of intraventricular orexin A in lesioned 
animals does improve accuracy at a shorter signal duration compared to the effects of orexin 
A infused into the basal forebrain. It is certainly possible that, with these different methods 
of administration, in lesioned versus intact animals, orexin A is providing beneficial effects 
through different neural mechanisms. Further investigation of the neural basis of the 
beneficial effects of intraventricular orexin A is needed.
These results add to the growing literature about the beneficial cognitive effects of orexin A 
(Piantadosi et al. 2015). The basal forebrain appears to be one brain structure that mediates 
some of the effects of orexin A on attention. Collectively, these findings support the 
conclusion that orexin A is a fruitful target for future research into treatments for disorders 
characterized by attentional deficits.
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Figure 1. 
The figure depicts the location of cannula placements for the six rats that were included in 
the analyses of attentional task performance (A). A photomicrograph, taken with a 2X 
objective, shows the cannula placement in one hemisphere of one animal, although all 
infusions were bilateral (B). The arrow indicates the infusion site. The section is 
approximately −1.3 mm from bregma.
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Figure 2. 
The figure depicts the difference score (block 1 - block 2) when the distracter was presented 
compared with the previous block of trials with no distracter for the SAT measure (A) and a 
similar difference score for percent hits (B). The x-axis depicts the orexin doses (n = 6).
Zajo et al. Page 15
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
The figure shows acetylcholinesterase fiber staining from the same lesioned animal, in 
primary motor cortex (A) or in the prelimbic region of the medial prefrontal cortex (B).
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Figure 4. 
The x-axis represents the average of the indicated sessions for sham- (darkened bars; n = 9) 
and lesioned (open bars; n = 10) animals. The y-axis depicts percent correct rejections.
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Figure 5. 
The figure depicts the difference score (block 1 - block 2) when the distracter was presented 
compared with the previous block of trials with no distracter for percent hits on trials when 
the 25ms signal was presented for sham-lesioned (n = 9) and for 192IgG-saporin-induced 
lesioned animals (n = 10). The x-axis depicts the orexin doses.
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